美国食品药品监督管理局(FDA)已为Corbus Pharmaceuticals的Nectin-4靶向抗体药物偶联物(ADC)CRB-701授予快速通道资格,用于治疗头颈部鳞状细胞癌。
这一快速通道资格的获得,将有助于加速CRB-701的研发进程,为头颈部鳞状细胞癌患者提供新的治疗选择。该药物专门针对Nectin-4蛋白,通过抗体药物偶联技术,有望为这类癌症患者带来更有效的治疗方案。
美国食品药品监督管理局(FDA)已为Corbus Pharmaceuticals的Nectin-4靶向抗体药物偶联物(ADC)CRB-701授予快速通道资格,用于治疗头颈部鳞状细胞癌。
这一快速通道资格的获得,将有助于加速CRB-701的研发进程,为头颈部鳞状细胞癌患者提供新的治疗选择。该药物专门针对Nectin-4蛋白,通过抗体药物偶联技术,有望为这类癌症患者带来更有效的治疗方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.